The goal of this study is to reduce Hepatitis C Virus (HCV) seroincidence among recently initiated (less than 5 years) injection drug users (IDUs). New injectors are at high risk for bloodborne viral infections during their first years of injecting when they are least likely to seek formal substance abuse treatment and are likely to be practicing risky drug-use behaviors. In this study, 347 out-of-treatment IDUs will be recruited using Respondent Driven Sampling in Providence, Rhode Island. The Primary Aim of the present application is: To test if a brief Motivational Intervention (MI) will reduce the cumulative incidence of HCV compared to an """"""""assessment only"""""""" condition using a randomized trial design. The Secondary Aims are: 1) to test the mechanism through which the effect of brief MI occurs, and to determine the extent to which readiness to change risk behaviors is associated with reduction in HCV incidence; 2) to describe specific patient characteristics associated with reduction in HCV risk behaviors; 3) to describe time trends in HCV risk behaviors across the two groups over the 24-month period. The occurrence of injection drug use in a population with traditionally poor linkage to primary care, an enormous burden of illness, and high HCV and other bloodborne pathogen transmission risk, compels health care providers and policymakers to explore innovative approaches to improve the health of this group. This proposal further develops a brief motivational risk reduction strategy for IDUs previously demonstrated by these investigators to reduce HIV risk behaviors, applies it to HCV risk behaviors, and uses biological outcomes to test efficacy of our approach.
| Zobaníková, Marie; Mikolka, Pavol; Cejková, Darina et al. (2012) Complete genome sequence of Treponema pallidum strain DAL-1. Stand Genomic Sci 7:12-21 |
| Šmajs, David; Zobaníková, Marie; Strouhal, Michal et al. (2011) Complete genome sequence of Treponema paraluiscuniculi, strain Cuniculi A: the loss of infectivity to humans is associated with genome decay. PLoS One 6:e20415 |
| Stein, Michael D; Herman, Debra S; Anderson, Bradley J (2009) A trial to reduce hepatitis C seroincidence in drug users. J Addict Dis 28:389-98 |
| Stein, Michael D; Herman, Debra S; Anderson, Bradley J (2009) A motivational intervention trial to reduce cocaine use. J Subst Abuse Treat 36:118-25 |
| Phillips, Kristina T; Anderson, Bradley J; Stein, Michael D (2008) Predictors of bacterial infections among HCV-negative injection drug users in Rhode Island. Am J Drug Alcohol Abuse 34:203-10 |
| Hayaki, Jumi; Anderson, Bradley J; Stein, Michael D (2008) Drug use expectancies among nonabstinent community cocaine users. Drug Alcohol Depend 94:109-15 |
| Stein, Michael D; Dubyak, Pamela; Herman, Deb et al. (2007) Perceived barriers to safe-injection practices among drug injectors who remain HCV-negative. Am J Drug Alcohol Abuse 33:517-25 |
| Rich, J D; Anderson, B J; Schwartzapfel, B et al. (2006) Sexual risk for hepatitis B virus infection among hepatitis C virus-negative heroin and cocaine users. Epidemiol Infect 134:478-84 |
| Pugatch, David; Anderson, Bradley J; O'Connell, Janet V et al. (2006) HIV and HCV testing for young drug users in Rhode Island. J Adolesc Health 38:302-4 |
| Lagu, Tara; Anderson, Bradley J; Stein, Michael (2006) Overdoses among friends: drug users are willing to administer naloxone to others. J Subst Abuse Treat 30:129-33 |
Showing the most recent 10 out of 12 publications
